EYE vs. RXST, STAA, WRBY, LUCY, ALC, COO, BLCO, INSP, MMSI, and KRYS
Should you be buying National Vision stock or one of its competitors? The main competitors of National Vision include RxSight (RXST), STAAR Surgical (STAA), Warby Parker (WRBY), Innovative Eyewear (LUCY), Alcon (ALC), Cooper Companies (COO), Bausch + Lomb (BLCO), Inspire Medical Systems (INSP), Merit Medical Systems (MMSI), and Krystal Biotech (KRYS). These companies are all part of the "medical" sector.
RxSight (NASDAQ:RXST) and National Vision (NASDAQ:EYE) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, community ranking, analyst recommendations, media sentiment, profitability, risk and earnings.
National Vision received 217 more outperform votes than RxSight when rated by MarketBeat users. However, 66.67% of users gave RxSight an outperform vote while only 65.89% of users gave National Vision an outperform vote.
RxSight has higher earnings, but lower revenue than National Vision. RxSight is trading at a lower price-to-earnings ratio than National Vision, indicating that it is currently the more affordable of the two stocks.
RxSight presently has a consensus price target of $60.63, indicating a potential upside of 3.69%. National Vision has a consensus price target of $19.60, indicating a potential upside of 29.89%. Given RxSight's higher possible upside, analysts clearly believe National Vision is more favorable than RxSight.
In the previous week, National Vision had 9 more articles in the media than RxSight. MarketBeat recorded 13 mentions for National Vision and 4 mentions for RxSight. National Vision's average media sentiment score of 1.56 beat RxSight's score of 0.61 indicating that RxSight is being referred to more favorably in the media.
78.8% of RxSight shares are held by institutional investors. 9.4% of RxSight shares are held by insiders. Comparatively, 2.3% of National Vision shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
RxSight has a beta of 1.21, suggesting that its share price is 21% more volatile than the S&P 500. Comparatively, National Vision has a beta of 1.47, suggesting that its share price is 47% more volatile than the S&P 500.
National Vision has a net margin of -3.44% compared to National Vision's net margin of -44.01%. RxSight's return on equity of 3.47% beat National Vision's return on equity.
Summary
National Vision beats RxSight on 10 of the 18 factors compared between the two stocks.
Get National Vision News Delivered to You Automatically
Sign up to receive the latest news and ratings for EYE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EYE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
National Vision Competitors List
Related Companies and Tools
